Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
84 hedge funds and large institutions have $297M invested in Eiger BioPharmaceuticals, Inc. in 2015 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 29 increasing their positions, 11 reducing their positions, and 10 closing their positions.
180% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 10
164% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 11
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
84% more call options, than puts
Call options by funds: $26.2M | Put options by funds: $14.2M
27% more funds holding
Funds holding: 66 → 84 (+18)
20% more capital invested
Capital invested by funds: $248M → $297M (+$49.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$19.4M |
| 2 |
Millennium Management
New York
|
+$16.4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.43M |
| 4 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
+$5.83M |
| 5 |
Renaissance Technologies
New York
|
+$5.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$11.8M |
| 2 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$5.86M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$5.64M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$3.1M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.94M |
EIGR Hedge Fund Activity: Q1 2015 in Review
84 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q1 2015, worth a combined $297M — up 20% from $248M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new EIGR positions and 10 closed out — a net gain of 18 holders — while 29 added to existing stakes and 11 trimmed.
The largest buyer was Mangrove Partners, opening a new position worth an estimated $19.4M. The largest seller was Tekla Capital Management, exiting entirely with an estimated $11.8M sold.
- 84 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q1 2015, up from 66 in Q4 2014.
- Funds reported $297M of Eiger BioPharmaceuticals, Inc. stock for Q1 2015, up 20% quarter-over-quarter.
- 28 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q1 2015 and 10 closed out, a net change of +18 holders.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q1 2015 was Mangrove Partners, an estimated $19.4M added.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q1 2015 was Tekla Capital Management, an estimated $11.8M sold.
Based on aggregated 13F filings for Q1 2015.